Article - 30/07/2012 How to prevent pathogens from developing antibiotic resistances For bacteria, the environment is rather like a big market where they can give and receive new survival strategies if need be. A group of researchers led by Prof. Dr. Elisabeth Grohmann at the Freiburg University Medical Centre is investigating how microorganisms exchange antibiotic resistance genes. In a project involving two hospitals in Mexico City, the molecular biologists are also investigating whether pathogens, resistance genes and…https://www.gesundheitsindustrie-bw.de/en/article/news/how-to-prevent-pathogens-from-developing-antibiotic-resistances
Press release - 17/07/2012 Schmallenberg virus: Identifying infected cows and sheep faster The world's first commercial detection method for the Schmallenberg virus is now available for all laboratories. Kornwestheim-based AnDiaTec GmbH & Co. KG, specialists in detection methods for pathogens in the veterinary field, has just received approval for its product from the Friedrich-Löffler-Institut under the German Ordinance on Working with Animal Pathogens (Tierseuchengesetz). The virus, which has led, among other things, to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/schmallenberg-virus-identifying-infected-cows-and-sheep-faster
Dossier - 30/04/2012 Human infectious diseases: new threats The serious EHEC outbreak in Germany in 2011, the 2009 swine flu pandemic, the bird flu pandemic in 2005 and 2006 and the SARS outbreak in China in 2003, all of which have fuelled the fear of devastating epidemics for many people in Germany, have fortunately all been contained – at least up until now. However, experts warn of new dangerous pathogens that are spreading as a result of globalization and global climate warming. This is leading to new…https://www.gesundheitsindustrie-bw.de/en/article/dossier/human-infectious-diseases-new-threats
Article - 30/04/2012 Antibiotic resistance in hospitals There is an alarming rise in infections caused by bacteria that are resistant to common antibiotics. A particular problem is nosocomial (hospital-acquired) infections of newborns, for which a Germany-wide surveillance system has been established. Novel natural substances with an antibiotic effect might be able to contain the danger.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotic-resistance-in-hospitals
Article - 30/04/2012 German Cardiac Society meeting 2012 - Medicine for sick hearts The recent German Cardiac Society meeting in Mannheim in April 2012 focused on the latest findings related to the prognosis, diagnosis and therapy of heart diseases. While great progress has been made in the therapy of disease symptoms, it will still take a long time before gene and stem cell therapies that target the causes of disease find their way into clinical application. The conference also presented the new German Centre for Cardiovascular…https://www.gesundheitsindustrie-bw.de/en/article/news/german-cardiac-society-meeting-2012-medicine-for-sick-hearts
Article - 21/11/2011 Johannes Huebner's interest in intestinal bacteria and their sweet-sour capsule Some Enterococcus species are common commensal organisms in human intestines and other species are used in raw-milk cheese where they enhance flavour development. On the negative side enterococci are also a common cause of hospital-acquired infections. Prof. Dr. Johannes Huebner from the Freiburg University Medical Centre is hoping that the bacterias capsular polysaccharides might at some point in the future be used as a vaccine opening the door…https://www.gesundheitsindustrie-bw.de/en/article/news/johannes-huebner-s-interest-in-intestinal-bacteria-and-their-sweet-sour-capsule
Press release - 15/11/2011 CureVac, Sanofi Pasteur and In-Cell-Art collaborate on a $33.1 million project CureVac GmbH today announced the signing of several agreements with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY). Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive® technology platform to the development of vaccines against several infectious diseases.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-sanofi-pasteur-and-in-cell-art-collaborate-on-a-33-1-million-project
Article - 14/11/2011 Marina Freudenberg and Chris Galanos – more than 40 years of bacterial defence research This years Nobel Prize in Medicine or Physiology was awarded to three renowned scientists one of whom is the American Bruce Beutler who was instrumental in clarifying the structure of the mammalian Toll-like 4 TLR4 receptor. Prof. Dr. med. Marina Freudenberg and Dr. Dr. h.c. Chris Galanos from the Freiburg-based Max Planck Institute MPI of Immunobiology and Epigenetics have co-authored the key publication that led to the award of the Nobel Prize…https://www.gesundheitsindustrie-bw.de/en/article/news/marina-freudenberg-and-chris-galanos-more-than-40-years-of-bacterial-defence-research
Press release - 03/11/2011 Curetis AG attracts Forbion and Roche as new investors Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, announced the expansion of its Series A financing round by € 9.6 million. The additional funds increase the round to a total of € 34.1 million and the total capital raised to date to € 36.6 million. https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-attracts-forbion-and-roche-as-new-investors
Press release - 24/10/2011 Curetis AG Opens Unyvero™ Cartridge Production Facility Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, announced the opening of its state-of-the-art production facility for disposable Unyvero™ cartridges in Bodelshausen (near Tuebingen, Germany).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-opens-unyvero-cartridge-production-facility
Press release - 20/06/2011 CureVac presents new data for prostate and lung cancer vaccines CureVac GmbH presented promising new data for prostate cancer vaccine CV9103 and lung cancer vaccine CV9201 at the ASCO Conference in Chicago. Final trial results confirm safety and excellent antigen-specific immunogenicity of prostate cancer vaccine CV9103. And initial promising data from phase I/IIa trial of lung cancer vaccine CV9201 further supports the potential of CureVac’s RNActive® vaccination technology in cancer immunotherapy and…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-presents-new-data-for-prostate-and-lung-cancer-vaccines
Article - 23/05/2011 Mosquitoes and exotic infectious diseases in Germany Exotic mosquitoes such as the Asian rock pool mosquito and the Asian tiger mosquito are invading many countries around the world including European ones. This is a direct result of rising temperatures and increasing international travel and transport of goods. Entomologists virologists and tropical medicine experts are working together on a number of projects aimed at monitoring the distribution of mosquitoes across Europe and reducing the risk…https://www.gesundheitsindustrie-bw.de/en/article/news/mosquitoes-and-exotic-infectious-diseases-in-germany
Press release - 19/05/2011 Curetis AG successfully increases Series A financing round to EUR 24.5 million Curetis AG, an innovative molecular diagnostics company focusing on the development and commercialization of in-vitro diagnostic products for infectious diseases, today announced an extension of its Series A financing, bringing the total size of the round to € 24.5 million. CD-Venture joined the funding as a new investor, while all of Curetis' existing VC investors participated in the round. Several private investors also continued to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/curetis-ag-successfully-increases-series-a-financing-round-to-eur-24-5-million
Press release - 26/04/2011 Green Light for Four New Centres of Health Research The decision has been taken: The German Centres of Health Research which are to be set up in the areas of infectious diseases, cardiovascular diseases, lung diseases and cancer will involve more than 100 universities, university hospitals and non-university research institutions at 27 locations. Federal Research Minister Annette Schavan decided on the funding of four new centres on Friday after considering recommendations submitted by panels of…https://www.gesundheitsindustrie-bw.de/en/article/press-release/green-light-for-four-new-centres-of-health-research
Press release - 07/04/2011 Novel compounds for fighting against parasitic diseases Parasites of the Trypanosomatidae family cause a number of serious human diseases. Researchers from Italy, Belgium, and Germany have published the identification of novel anti-parasitic compounds targeting an enzyme unique to the parasites. These compounds are promising for the development of drugs with fewer side-effects than current medical treatments.https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-compounds-for-fighting-against-parasitic-diseases
Article - 04/04/2011 FreiBiotics GmbH – new drugs against resistant bacteria Bacteria adapt quickly to their environment and also to antibiotics. Many of the antibiotics used to treat bacterial infections have become ineffective as a great many bacteria have become resistant to them. Freiburg-based FreiBiotics GmbH is looking for completely new classes of antimicrobial substances. A screening method that has been developed over the last few years based on biosensors makes the identification of new substance classes more…https://www.gesundheitsindustrie-bw.de/en/article/news/freibiotics-gmbh-new-drugs-against-resistant-bacteria
Article - 14/02/2011 A molecule that enables local virus defence Dr. Markus Mordstein has spent the last four years as a doctoral student at the University of Freiburg investigating the previously relatively unknown interferon lambda. He has been able to show that this molecule has similar protective functions to type I interferons and he has also found that it is far more selective in terms of the site where it exerts its effect.https://www.gesundheitsindustrie-bw.de/en/article/news/a-molecule-that-enables-local-virus-defence
Article - 29/11/2010 Against chronic liver inflammation and liver cancer Chronic hepatitis B and C are the major causes of liver cancer. In contrast to hepatitis B viruses, there is no hepatitis C virus vaccination available. New research carried out by Professor Bartenschlager and his colleagues from Heidelberg might give rise to new strategies for the development of vaccines and medications for the prevention and treatment of chronic hepatitis C virus infections.https://www.gesundheitsindustrie-bw.de/en/article/news/against-chronic-liver-inflammation-and-liver-cancer
Press release - 08/09/2010 Gene doping detectable with a simple blood test Scientists at the universities of Tübingen and Mainz have developed a blood test that is able to provide conclusive proof of gene doping. The test is still effective even if the actual doping took place some time before the test. The new test is based on a procedure developed in Tübingen in 2006 that enables transgenic DNA to be detected in the blood. The efficiency of this procedure has now been proven for the first time in laboratory mice. https://www.gesundheitsindustrie-bw.de/en/article/press-release/gene-doping-detectable-with-a-simple-blood-test
Press release - 23/08/2010 Dr. Carsten Daub – team leader at the Bioinformatics Core Facility of RIKEN in Yokohama Dr. Carsten Daub a German bioinformatician who first studied chemistry at the TU Berlin did his doctoral degree in 2004 at the MPI of Molecular Plant Physiology in Potsdam Germany and after a two years post-doctoral training at the Karolinska Institutets Center or Genomics and Bioinformation in Stockholm Sweden joined the Genome Sciences Center at RIKEN in April 2006 on a five years contract.https://www.gesundheitsindustrie-bw.de/en/article/press-release/dr-carsten-daub-team-leader-at-the-bioinformatics-core-facility-of-riken-in-yokohama
Article - 23/08/2010 Antibiotics for the prevention of malaria Researchers from Heidelberg and Berlin have shown that if malaria-infected mice are administered an antibiotic, no parasites appear in the blood and the mice are protected from this life-threatening disease. The scientists believe that antibiotics also have the potential to strengthen the human immune system as well as making it possible to provide a natural needle-free vaccination against malaria.https://www.gesundheitsindustrie-bw.de/en/article/news/antibiotics-for-the-prevention-of-malaria
Article - 03/07/2010 Erbasens: Using the power of nature Before setting up her own company biologist Dr. Elke Schulz amassed a wealth of knowledge in the pharmaceutical industry. Now she harnesses the power of plants to develop and sell dietary supplements and natural cosmetics. Her company Erbasens specialises in combining high-quality oils and plant essences to create products such as Paramirum that safeguards the effectiveness of the immune system and promotes the bodys defence systems.https://www.gesundheitsindustrie-bw.de/en/article/news/erbasens-using-the-power-of-nature
Article - 12/06/2010 Correcting enzyme defects using stem cells Bone marrow transplantation was originally developed for the treatment of leukaemias and other malignant diseases of the haemotopoietic system. Thanks to increasing technological process it has been possible to considerably expand the treatment spectrum over the last few years. Dr. Ingo Müller paediatrician at the University Hospital in Tübingen now uses bone marrow transplantation for the therapy of genetic metabolic diseases with highly…https://www.gesundheitsindustrie-bw.de/en/article/news/correcting-enzyme-defects-using-stem-cells
Press release - 07/06/2010 Addition of renowned experts to Medical Advisory Board and achievement of international quality standards generate added optimism With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through to market entry. Quality Certification for its diagnostic product development represents an additional milestone in Curetis' commercial strategy. At the same time, Curetis has added internationally recognized expertise in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/addition-of-renowned-experts-to-medical-advisory-board-and-achievement-of-international-quality-stan
Press release - 12/05/2010 CureVac raises EUR 27.6 Million in Financing Round CureVac GmbH, the mRNA vaccine company, today announced the closing of a EUR 27.6 million (US$ 35.25 million) financing round with its major shareholder, dievini Hopp BioTech holding GmbH & Co. KG.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-eur-27-6-million-in-financing-round